DEFA14A: Mural Oncology Urges Shareholder Vote on Acquisition

Mural Oncology plc reminds shareholders to vote on proposals for both the Scheme Meeting and Extraordinary General Meeting by October 23, 2025, concerning an acquisition.

Summary

• Mural Oncology plc is reminding shareholders to vote on proposals for two separate special meetings: a Scheme Meeting and an Extraordinary General Meeting.
• Both meetings are scheduled for Friday, October 24, 2025, at 10:30 a.m. and 10:45 a.m. Irish local time, respectively, at the offices of Arthur Cox LLP in Dublin, Ireland.
• Shareholders must vote separately for each meeting, either by mailing two distinct proxy cards or by following instructions for both meetings if voting by telephone or over the Internet.
• The voting deadline is 11:59 p.m. Irish local time (6:59 p.m. U.S. Eastern Time) on October 23, 2025.
• Proxy materials containing important information regarding the acquisition proposals were previously sent to shareholders on or about September 23, 2025.
• The communication serves as an informational notice and does not constitute an offer, invitation, or solicitation to purchase or sell securities.
• The acquisition will be executed solely through a Proxy Statement distributed to Mural's shareholders, which includes the Scheme and full terms and conditions.
• Mural has filed a definitive Proxy Statement with the SEC related to these meetings and the acquisition, urging shareholders to read it carefully before making any voting decision.

Sentiment

Score: 7

Explanation: The filing is a procedural reminder for shareholders to vote on an acquisition, indicating the transaction is progressing as planned. It provides clear instructions and emphasizes the importance of shareholder participation, which is a neutral to slightly positive sign of corporate action execution.

Positives

• The company is proactively communicating with shareholders, providing clear instructions and deadlines for an important corporate action.
• Contact information for proxy solicitor and investor relations is provided for shareholder assistance with voting or questions.

Risks

• Uncertainties exist regarding the exact timing and ultimate completion of both the Scheme Meeting and the Extraordinary General Meeting.
• There is a risk that Mural Shareholders may not approve the required resolutions at either the Scheme Meeting or the Extraordinary General Meeting.
• Closing conditions for the Acquisition may not be satisfied or waived, including the potential failure to receive sanction of the Scheme by the High Court.
• Ongoing costs to Mural could lead to the company's Closing Net Cash on the Closing Net Cash Date not exceeding the Estimated Closing Net Cash, which would result in no Additional Price Per Share being paid to Mural Shareholders.
• General business risks and uncertainties for Mural, as detailed in its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and subsequent SEC filings, including the Proxy Statement, could impact the acquisition.
• Risks and uncertainties related to XOMA Royalty, as described in its most recent Quarterly Report on Form 10-Q and other SEC filings, could affect the transaction.

Future Outlook

Mural, XOMA Royalty, and Sub intend to consummate the Acquisition, which is subject to approval by Mural Shareholders and the satisfaction of closing conditions. There is a potential for an Additional Price Per Share to be paid to Mural Shareholders if Mural's Closing Net Cash exceeds the Estimated Closing Net Cash. The expected timing of the closing of the Acquisition is also a forward-looking statement.

Management Comments

• "YOUR VOTES ARE IMPORTANT!"
• "Please be sure to vote on the proposals for consideration at both the Scheme Meeting and the Extraordinary General Meeting no later than 11:59 p.m. Irish local time (6:59 p.m. U.S. Eastern Time) on October 23, 2025 to be counted at the special meetings."
• "Mural strongly encourages each shareholder to read this letter and the materials previously circulated carefully and in their entirety."
• "We appreciate your ongoing support for Mural." Caroline Loew, Ph.D., Chief Executive Officer

Industry Context

This filing represents a standard procedural step in a corporate acquisition, common across industries when a publicly traded company is being acquired. It highlights the regulatory requirements for obtaining shareholder approval for such transactions, particularly under both Irish and U.S. securities laws, ensuring transparency and adherence to corporate governance best practices during a change of control.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the acquisition, as their vote is required for the transaction to proceed, and they may receive an Additional Price Per Share upon closing.

Next Steps

• Shareholders are required to cast their votes on the proposals for both the Scheme Meeting and the Extraordinary General Meeting by October 23, 2025.
• The Scheme Meeting and Extraordinary General Meeting will be held on October 24, 2025, to consider and vote on the acquisition proposals.
• Completion of the Acquisition is contingent upon shareholder approval and the satisfaction or waiver of all closing conditions, including the sanction of the Scheme by the High Court.
• If conditions are met, the Acquisition will be consummated, potentially leading to the payment of an Additional Price Per Share to Mural Shareholders if Closing Net Cash exceeds Estimated Closing Net Cash.

Key Dates

Recommendation

This filing is a procedural update reminding shareholders to vote on an acquisition. It does not introduce new financial performance data or strategic shifts that would fundamentally alter the company's valuation beyond the acquisition terms already disclosed. Investors should hold their shares to ensure participation in the acquisition process and potential receipt of any Additional Price Per Share, or consider selling if they do not wish to be part of the acquiring entity or disagree with the acquisition terms.

Keywords

Mural Oncology, Acquisition, Shareholder Vote, Proxy Statement, SEC Filing, Corporate Governance, Scheme Meeting, Extraordinary General Meeting, XOMA Royalty, Corporate Action